Loading...

Immunovant, Inc.

IMVT•NASDAQ
Healthcare
Biotechnology
$28.58
$-0.33(-1.14%)
U.S. Market opens in 49h 27m

Immunovant, Inc. (IMVT) Stock Overview

Explore Immunovant, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap5.8B
P/E Ratio-11.17
EPS (TTM)$-2.67
ROE-0.66%
Fundamental Analysis

AI Price Forecasts

1 Month$21.39
3 Months$32.34
1 Year Target$14.99

IMVT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Immunovant, Inc. (IMVT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 59.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $14.99.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -11.17 and a market capitalization of 5.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.14%
5-Day Change
2.81%
1-Month Change
19.88%
3-Month Change
9.88%
6-Month Change
50.90%
Year-to-Date (YTD) Change
12.43%
1-Year Change
89.65%
3-Year Change
79.30%
5-Year Change
79.41%
All-Time (Max) Change
187.24%

Contact Information

https://immunovant.com
917 580 3099
320 West 37th Street, New York City, NY, 10018

Company Facts

362 Employees
IPO DateJun 21, 2019
CountryUS
Actively Trading

Frequently Asked Questions